MAX
Company Analysis IDEAYA Biosciences, Inc.
1. Summary
Advantages
- Price (30.27 $) is less than fair price (31.24 $)
- The stock's return over the last year (52.19%) is higher than the sector average (-26.18%).
- Current debt level 1.71% is below 100% and has decreased over 5 years from 2.25%.
Disadvantages
- Dividends (0%) are below the sector average (0.54%).
- The company's current efficiency (ROE=-32.67%) is lower than the sector average (ROE=104.5%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| IDEAYA Biosciences, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -4% | -21.3% | -3% |
| 90 days | -11% | -32.7% | -0.3% |
| 1 year | 52.2% | -26.2% | 12.4% |
IDYA vs Sector: IDEAYA Biosciences, Inc. has outperformed the "Healthcare" sector by 78.37% over the past year.
IDYA vs Market: IDEAYA Biosciences, Inc. has outperformed the market by 39.82% over the past year.
Stable price: IDYA is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: IDYA with weekly volatility of 1% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Below fair price: The current price (30.27 $) is lower than the fair price (31.24 $).
Price not significantly lower than the fair price: The current price (30.27 $) is slightly lower than the fair price by 3.2%.
5.2. P/E
P/E vs Sector: The company's P/E (-7.27) is lower than that of the sector as a whole (33.29).
P/E vs Market: The company's P/E (-7.27) is higher than that of the market as a whole (-107.89).
5.3. P/BV
P/BV vs Sector: The company's P/BV (1.98) is lower than that of the sector as a whole (254.5).
P/BV vs Market: The company's P/BV (1.98) is lower than that of the market as a whole (72.83).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (299.87) is higher than that of the sector as a whole (129.32).
P/S vs Market: The company's P/S indicator (299.87) is higher than that of the market as a whole (116.06).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-6.22) is higher than that of the sector as a whole (-27.64).
EV/Ebitda vs Market: The company's EV/Ebitda (-6.22) is higher than that of the market as a whole (-81.5).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Rising and has grown by 89.79% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (89.79%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (241.72%).
6.4. ROE
ROE vs Sector: The company's ROE (-32.67%) is lower than that of the sector as a whole (104.5%).
ROE vs Market: The company's ROE (-32.67%) is lower than that of the market as a whole (-6.44%).
6.6. ROA
ROA vs Sector: The company's ROA (-30.95%) is lower than that of the sector as a whole (-2.18%).
ROA vs Market: The company's ROA (-30.95%) is lower than that of the market as a whole (38.41%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (-21.56%) is lower than that of the sector as a whole (1.04%).
ROIC vs Market: The company's ROIC (-21.56%) is lower than that of the market as a whole (9.36%).
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.54%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
9. Insider trades
9.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
9.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 09.08.2023 | Stone Paul A. Chief Financial Officer |
Sale | 25.05 | 62 625 | 2 500 |
| 09.08.2023 | Throne Jason Chief Legal Officer |
Sale | 25.09 | 125 450 | 5 000 |
| 09.08.2023 | Throne Jason Chief Legal Officer |
Purchase | 13.34 | 66 700 | 5 000 |
| 10.07.2023 | Throne Jason Chief Legal Officer |
Sale | 23 | 218 155 | 9 485 |
| 10.07.2023 | Throne Jason Chief Legal Officer |
Purchase | 10.09 | 95 704 | 9 485 |
Based on sources: porti.ru
